A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

NCT07543250 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Inavolisib in Combination With ET
DRUG: Inavolisib in Combination With ET+CDK4/6i

Sponsor

xuliang